Skip to main content

Advertisement

SpringerLink
Log in

MiR-142-3p ameliorates high glucose-induced renal tubular epithelial cell injury by targeting BOD1

  • Original article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

Tubular injury plays a crucial role in the pathogenesis of diabetic nephropathy (DN). It is well known that many microRNAs (miRNAs) exert crucial effects on tubular injury. This study intends to explore the effect of miR-142-3p on the apoptosis and oxidative stress of high glucose (HG)-treated renal tubular epithelial cells (HK-2) and its underlying mechanism.

Materials and methods

HK-2 cells were exposed to HG to mimic cell injury. MTT assays and flow cytometry analyses were conducted to measure cell viability and cell apoptosis, respectively. RT-qPCR and western blot analyses were carried out to detect RNA and protein levels, respectively. The levels of oxidative stress markers were evaluated by ELISA. The binding between miR-142-3p and biorientation of chromosomes in cell division 1 (BOD1) was validated by a luciferase reporter assay.

Result

MiR-142-3p is low-expressed in HG-stimulated HK-2 cells. Functionally, miR-142-3p overexpression attenuates the apoptosis and oxidative stress of HG-stimulated HK-2 cells. Mechanistically, BOD1 was confirmed to be targeted by miR-142-3p in HK-2 cells. Moreover, BOD1 overexpression reversed the suppressive effect of miR-142-3p overexpression on the apoptosis and oxidative stress of HK-2 cells treated with HG.

Conclusion

MiR-142-3p ameliorates HG-induced renal tubular epithelial cell injury by targeting BOD1. The finding might provide novel insight into the role of miR-142-3p/BOD1 axis in DN treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Lin YC, Chang YH, Yang SY, Wu KD, Chu TS. Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc. 2018;117(8):662–75. https://doi.org/10.1016/j.jfma.2018.02.007.

    Article  CAS  PubMed  Google Scholar 

  2. Qi C, Mao X, Zhang Z, Wu H. Classification and differential diagnosis of diabetic nephropathy. J Diabetes Res. 2017;2017:8637138. https://doi.org/10.1155/2017/8637138.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Papadopoulou-Marketou N, Chrousos GP, Kanaka-Gantenbein C. Diabetic nephropathy in type 1 diabetes: a review of early natural history, pathogenesis, and diagnosis. Diabetes Metab Res Rev. 2017. https://doi.org/10.1002/dmrr.2841.

    Article  PubMed  Google Scholar 

  4. Papadopoulou-Marketou N, Paschou SA, Marketos N, Adamidi S, Adamidis S, Kanaka-Gantenbein C. Diabetic nephropathy in type 1 diabetes. Minerva Med. 2018;109(3):218–28. https://doi.org/10.23736/s0026-4806.17.05496-9.

    Article  PubMed  Google Scholar 

  5. Ioannou K. Diabetic nephropathy: is it always there? Assumptions, weaknesses and pitfalls in the diagnosis. Hormones (Athens). 2017;16(4):351–61. https://doi.org/10.14310/horm.2002.1755.

    Article  Google Scholar 

  6. Meza Letelier CE, San Martín Ojeda CA, Ruiz Provoste JJ, Frugone Zaror CJ. Pathophysiology of diabetic nephropathy: a literature review. Medwave. 2017;17(1):e6839. https://doi.org/10.5867/medwave.2017.01.6839.

    Article  PubMed  Google Scholar 

  7. Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141(4):1202–7. https://doi.org/10.1016/j.jaci.2017.08.034.

    Article  CAS  PubMed  Google Scholar 

  8. Mohr AM, Mott JL. Overview of microRNA biology. Semin Liver Dis. 2015;35(1):3–11. https://doi.org/10.1055/s-0034-1397344.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Regazzi R. MicroRNAs as therapeutic targets for the treatment of diabetes mellitus and its complications. Expert Opin Ther Targets. 2018;22(2):153–60. https://doi.org/10.1080/14728222.2018.1420168.

    Article  CAS  PubMed  Google Scholar 

  10. Rosado JA, Diez-Bello R, Salido GM, Jardin I. Fine-tuning of microRNAs in type 2 diabetes mellitus. Curr Med Chem. 2019;26(22):4102–18. https://doi.org/10.2174/0929867325666171205163944.

    Article  CAS  PubMed  Google Scholar 

  11. Kumar M, Nath S, Prasad HK, Sharma GD, Li Y. MicroRNAs: a new ray of hope for diabetes mellitus. Protein Cell. 2012;3(10):726–38. https://doi.org/10.1007/s13238-012-2055-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Simonson B, Das S. MicroRNA therapeutics: the next magic bullet? Mini Rev Med Chem. 2015;15(6):467–74. https://doi.org/10.2174/1389557515666150324123208.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Yu J, Yu C, Feng B, Zhan X, Luo N, Yu X, et al. Intrarenal microRNA signature related to the fibrosis process in chronic kidney disease: identification and functional validation of key miRNAs. BMC Nephrol. 2019;20(1):336. https://doi.org/10.1186/s12882-019-1512-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Zanchi C, Macconi D, Trionfini P, Tomasoni S, Rottoli D, Locatelli M, et al. MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy. Diabetologia. 2017;60(6):1114–25. https://doi.org/10.1007/s00125-017-4248-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Zhao Y, Yin Z, Li H, Fan J, Yang S, Chen C, et al. MiR-30c protects diabetic nephropathy by suppressing epithelial-to-mesenchymal transition in db/db mice. Aging Cell. 2017;16(2):387–400. https://doi.org/10.1111/acel.12563.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Sun J, Zhao F, Zhang W, Lv J, Lv J, Yin A. BMSCs and miR-124a ameliorated diabetic nephropathy via inhibiting notch signalling pathway. J Cell Mol Med. 2018;22(10):4840–55. https://doi.org/10.1111/jcmm.13747.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Zhou L, Xu DY, Sha WG, Shen L, Lu GY, Yin X, et al. High glucose induces renal tubular epithelial injury via Sirt1/NF-kappaB/microR-29/Keap1 signal pathway. J Transl Med. 2015;13:352. https://doi.org/10.1186/s12967-015-0710-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kantharidis P, Hagiwara S, Brennan E, McClelland AD. Study of microRNA in diabetic nephropathy: isolation, quantification and biological function. Nephrology (Carlton). 2015;20(3):132–9. https://doi.org/10.1111/nep.12374.

    Article  CAS  Google Scholar 

  19. Rudnicki M, Beckers A, Neuwirt H, Vandesompele J. RNA expression signatures and posttranscriptional regulation in diabetic nephropathy. Nephrol Dial Transplant. 2015;30(Suppl 4):35–42. https://doi.org/10.1093/ndt/gfv079.

    Article  CAS  Google Scholar 

  20. Zeng Y, Feng Z, Liao Y, Yang M, Bai Y, He Z. Diminution of microRNA-98 alleviates renal fibrosis in diabetic nephropathy by elevating Nedd4L and inactivating TGF-β/Smad2/3 pathway. Cell Cycle. 2020;19(24):3406–18. https://doi.org/10.1080/15384101.2020.1838780.

    Article  CAS  PubMed  Google Scholar 

  21. Liu F, Zhang ZP, Xin GD, Guo LH, Jiang Q, Wang ZX. miR-192 prevents renal tubulointerstitial fibrosis in diabetic nephropathy by targeting Egr1. Eur Rev Med Pharmacol Sci. 2018;22(13):4252–60. https://doi.org/10.26355/eurrev_201807_15420.

    Article  CAS  PubMed  Google Scholar 

  22. Zhao D, Jia J, Shao H. miR-30e targets GLIPR-2 to modulate diabetic nephropathy: in vitro and in vivo experiments. J Mol Endocrinol. 2017;59(2):181–90. https://doi.org/10.1530/jme-17-0083.

    Article  CAS  PubMed  Google Scholar 

  23. Gholaminejad A, Abdul Tehrani H, Gholami FM. Identification of candidate microRNA biomarkers in renal fibrosis: a meta-analysis of profiling studies. Biomarkers. 2018;23(8):713–24. https://doi.org/10.1080/1354750x.2018.1488275.

    Article  CAS  PubMed  Google Scholar 

  24. Liang YZ, Li JJ, Xiao HB, He Y, Zhang L, Yan YX. Identification of stress-related microRNA biomarkers in type 2 diabetes mellitus: a systematic review and meta-analysis. J Diabetes. 2020;12(9):633–44. https://doi.org/10.1111/1753-0407.12643.

    Article  CAS  PubMed  Google Scholar 

  25. Zhu H, Leung SW. Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies. Diabetologia. 2015;58(5):900–11. https://doi.org/10.1007/s00125-015-3510-2.

    Article  CAS  PubMed  Google Scholar 

  26. Zhang T, Ji C, Shi R. miR-142-3p promotes pancreatic β cell survival through targeting FOXO1 in gestational diabetes mellitus. Int J Clin Exp Pathol. 2019;12(5):1529–38.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Zhou L, Xu DY, Sha WG, Shen L, Lu GY, Yin X. Long non-coding MIAT mediates high glucose-induced renal tubular epithelial injury. Biochem Biophys Res Commun. 2015;468(4):726–32. https://doi.org/10.1016/j.bbrc.2015.11.023.

    Article  CAS  PubMed  Google Scholar 

  28. Vejnar CE, Zdobnov EM. MiRmap: comprehensive prediction of microRNA target repression strength. Nucleic Acids Res. 2012;40(22):11673–83. https://doi.org/10.1093/nar/gks901.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat Genet. 2007;39(10):1278–84. https://doi.org/10.1038/ng2135.

    Article  CAS  PubMed  Google Scholar 

  30. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell. 2006;126(6):1203–17. https://doi.org/10.1016/j.cell.2006.07.031.

    Article  CAS  PubMed  Google Scholar 

  31. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20. https://doi.org/10.1016/j.cell.2004.12.035.

    Article  CAS  PubMed  Google Scholar 

  32. Qi C, Mao X. Classification and Differential Diagnosis of Diabetic. Nephropathy. 2017;2017:8637138. https://doi.org/10.1155/2017/8637138.

    Article  Google Scholar 

  33. Flyvbjerg A. The role of the complement system in diabetic nephropathy. Nat Rev Nephrol. 2017;13(5):311–8. https://doi.org/10.1038/nrneph.2017.31.

    Article  CAS  PubMed  Google Scholar 

  34. Tang J, Yao D, Yan H, Chen X, Wang L, Zhan H. The role of MicroRNAs in the pathogenesis of diabetic nephropathy. Int J Endocrinol. 2019;2019:8719060. https://doi.org/10.1155/2019/8719060.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Lu Y, Liu D, Feng Q, Liu Z. Diabetic nephropathy: perspective on extracellular vesicles. Front Immunol. 2020;11:943. https://doi.org/10.3389/fimmu.2020.00943.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Sagoo MK, Gnudi L. Diabetic nephropathy: is there a role for oxidative stress? Free Radical Biol Med. 2018;116:50–63. https://doi.org/10.1016/j.freeradbiomed.2017.12.040.

    Article  CAS  Google Scholar 

  37. Magee C, Grieve DJ, Watson CJ, Brazil DP. Diabetic Nephropathy: a tangled web to unweave. Cardiovasc Drugs Ther. 2017;31(5–6):579–92. https://doi.org/10.1007/s10557-017-6755-9.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Jha JC, Banal C, Chow BS, Cooper ME, Jandeleit-Dahm K. Diabetes and kidney disease: role of oxidative stress. Antioxid Redox Signal. 2016;25(12):657–84. https://doi.org/10.1089/ars.2016.6664.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Bao L, Li J, Zha D, Zhang L, Gao P, Yao T, et al. Chlorogenic acid prevents diabetic nephropathy by inhibiting oxidative stress and inflammation through modulation of the Nrf2/HO-1 and NF-ĸB pathways. Int Immunopharmacol. 2018;54:245–53. https://doi.org/10.1016/j.intimp.2017.11.021.

    Article  CAS  PubMed  Google Scholar 

  40. Hou Y, Shi Y, Han B, Liu X, Qiao X, Qi Y, et al. The antioxidant peptide SS31 prevents oxidative stress, downregulates CD36 and improves renal function in diabetic nephropathy. Nephrol Dial Transplant. 2018;33(11):1908–18. https://doi.org/10.1093/ndt/gfy021.

    Article  CAS  PubMed  Google Scholar 

  41. Al-Rasheed NM, Al-Rasheed NM, Bassiouni YA, Hasan IH, Al-Amin MA, Al-Ajmi HN, et al. Simvastatin ameliorates diabetic nephropathy by attenuating oxidative stress and apoptosis in a rat model of streptozotocin-induced type 1 diabetes. Biomed Pharmacother. 2018;105:290–8. https://doi.org/10.1016/j.biopha.2018.05.130.

    Article  CAS  PubMed  Google Scholar 

  42. Wang Y, Li Y, Yang Z, Wang Z, Chang J, Zhang T, et al. Pyridoxamine treatment of HK-2 human proximal tubular epithelial cells reduces oxidative stress and the inhibition of autophagy induced by high glucose levels. Med Sci Monit. 2019;25:1480–8. https://doi.org/10.12659/msm.914799.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Chen F, Sun Z, Zhu X, Ma Y. Astilbin inhibits high glucose-induced autophagy and apoptosis through the PI3K/Akt pathway in human proximal tubular epithelial cells. Biomed Pharmacother. 2018;106:1175–81. https://doi.org/10.1016/j.biopha.2018.07.072.

    Article  CAS  PubMed  Google Scholar 

  44. Kimura T, Takabatake Y, Takahashi A, Kaimori JY, Matsui I, Namba T, et al. Autophagy protects the proximal tubule from degeneration and acute ischemic injury. J Am Soc Nephrol. 2011;22(5):902–13. https://doi.org/10.1681/asn.2010070705.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Kitada M, Ogura Y, Monno I, Koya D. Regulating autophagy as a therapeutic target for diabetic nephropathy. Curr Diab Rep. 2017;17(7):53. https://doi.org/10.1007/s11892-017-0879-y.

    Article  CAS  PubMed  Google Scholar 

  46. Wei Z, Qin X, Kang X, Zhou H, Wang S, Wei D. MiR-142-3p inhibits adipogenic differentiation and autophagy in obesity through targeting KLF9. Mol Cell Endocrinol. 2020;518: 111028. https://doi.org/10.1016/j.mce.2020.111028.

    Article  CAS  PubMed  Google Scholar 

  47. Su Q, Liu Y, Lv XW, Ye ZL, Sun YH, Kong BH, et al. Inhibition of lncRNA TUG1 upregulates miR-142-3p to ameliorate myocardial injury during ischemia and reperfusion via targeting HMGB1- and Rac1-induced autophagy. J Mol Cell Cardiol. 2019;133:12–25. https://doi.org/10.1016/j.yjmcc.2019.05.021.

    Article  CAS  PubMed  Google Scholar 

  48. Plotnikova OM, Skoblov MY. Efficiency of the miRNA- mRNA interaction prediction programs. Mol Biol. 2018;52(3):543–54. https://doi.org/10.7868/s0026898418030187.

    Article  CAS  Google Scholar 

  49. Yang Z, Guo Z, Dong J, Sheng S, Wang Y, Yu L, et al. miR-374a regulates inflammatory response in diabetic nephropathy by targeting MCP-1 expression. Front Pharmacol. 2018;9:900. https://doi.org/10.3389/fphar.2018.00900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Wang J, Duan L, Guo T, Gao Y, Tian L, Liu J, et al. Downregulation of miR-30c promotes renal fibrosis by target CTGF in diabetic nephropathy. J Diabetes Complicat. 2016;30(3):406–14. https://doi.org/10.1016/j.jdiacomp.2015.12.011.

    Article  Google Scholar 

  51. Qin B, Shu Y, Long L, Li H, Men X, Feng L, et al. MicroRNA-142-3p induces atherosclerosis-associated endothelial cell apoptosis by directly targeting rictor. Cell Physiol Biochem. 2018;47(4):1589–603. https://doi.org/10.1159/000490932.

    Article  CAS  PubMed  Google Scholar 

  52. Sukma Dewi I, Celik S, Karlsson A, Hollander Z, Lam K, McManus JW, et al. Exosomal miR-142-3p is increased during cardiac allograft rejection and augments vascular permeability through down-regulation of endothelial RAB11FIP2 expression. Cardiovasc Res. 2017;113(5):440–52. https://doi.org/10.1093/cvr/cvw244.

    Article  CAS  PubMed  Google Scholar 

  53. Pan D, Du Y, Ren Z, Chen Y, Li X, Wang J, et al. Radiation induces premature chromatid separation via the miR-142-3p/Bod1 pathway in carcinoma cells. Oncotarget. 2016;7(37):60432–45. https://doi.org/10.18632/oncotarget.11080.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Di J, Rutherford S, Chu C. Review of the cervical cancer burden and population-based cervical cancer screening in China. Asian Pac J Cancer Prev. 2015;16(17):7401–7. https://doi.org/10.7314/apjcp.2015.16.17.7401.

    Article  PubMed  Google Scholar 

  55. Porter IM, Schleicher K, Porter M, Swedlow JR. Bod1 regulates protein phosphatase 2A at mitotic kinetochores. Nat Commun. 2013;4:2677. https://doi.org/10.1038/ncomms3677.

    Article  CAS  PubMed  Google Scholar 

  56. Gao Y, Zhao H, Li Y. LncRNA MCM3AP-AS1 regulates miR-142-3p/HMGB1 to promote LPS-induced chondrocyte apoptosis. BMC Musculoskelet Disord. 2019;20(1):605. https://doi.org/10.1186/s12891-019-2967-4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research was supported by Henan Science and Technology Research Project (No. 162102310287), Henan health and Family Planning Commission Provincial Ministry Co Construction Project (No.201701022), Henan Medical Science and Technology Research Project (No.2018020395).

Author information

Authors and Affiliations

  1. Department of Pharmacy, Henan Provincial People’s Hospital (Zhengzhou University People’s Hospital), No. 7 Weiwu Road, Zhengzhou, 450003, Henan, China

    Ningmin Zhao, Qing Luo, Ruijuan Lin, Qiaoyan Li & Peizhi Ma

Authors
  1. Ningmin Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qing Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ruijuan Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qiaoyan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peizhi Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peizhi Ma.

Ethics declarations

Conflict of interest

The authors report no declarations of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, N., Luo, Q., Lin, R. et al. MiR-142-3p ameliorates high glucose-induced renal tubular epithelial cell injury by targeting BOD1. Clin Exp Nephrol 25, 1182–1192 (2021). https://doi.org/10.1007/s10157-021-02102-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-021-02102-y

Keywords

Search

Navigation